MA24437A1 - Procede de la preparation et de la formulation de dihydrate d'eprosartan - Google Patents

Procede de la preparation et de la formulation de dihydrate d'eprosartan

Info

Publication number: MA24437A1
Authority: MA; Morocco
Prior art keywords: formulation; preparation; eprosartan; dihydrate; eprosartan dihydrate
Prior art date: 1996-03-29

Application number

MA24539A

Other languages

English (en)

Inventor

R Palepu Nageswara

M Venkatech Gopadi

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-03-29

Filing date

1997-03-26

Publication date

1998-10-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21765344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA24437(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-03-26 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

1998-10-01 Publication of MA24437A1 publication Critical patent/MA24437A1/fr

Links

239000002080 C09CA02 - Eprosartan Substances 0.000 title 1
-1 EPROSARTAN DIHYDRATE Chemical class 0.000 title 1
229960004563 eprosartan Drugs 0.000 title 1
238000009472 formulation Methods 0.000 title 1
238000000034 method Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Hospice & Palliative Care (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)
Saccharide Compounds (AREA)

MA24539A 1996-03-29 1997-03-26 Procede de la preparation et de la formulation de dihydrate d'eprosartan MA24437A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US1441496P	1996-03-29	1996-03-29

Publications (1)

Publication Number	Publication Date
MA24437A1 true MA24437A1 (fr)	1998-10-01

Family

ID=21765344

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA24539A MA24437A1 (fr)	1996-03-29	1997-03-26	Procede de la preparation et de la formulation de dihydrate d'eprosartan

Country Status (35)

Country	Link
EP (1)	EP0889880B1 (fr)
JP (1)	JP4316013B2 (fr)
CN (2)	CN1214682A (fr)
AP (1)	AP901A (fr)
AR (1)	AR006439A1 (fr)
AT (1)	ATE239723T1 (fr)
AU (1)	AU726694B2 (fr)
BG (1)	BG64095B1 (fr)
BR (1)	BR9708336A (fr)
CA (1)	CA2250395C (fr)
CZ (1)	CZ293345B6 (fr)
DE (1)	DE69721749T2 (fr)
DK (1)	DK0889880T3 (fr)
DZ (1)	DZ2199A1 (fr)
EA (1)	EA001958B1 (fr)
EG (1)	EG23889A (fr)
ES (1)	ES2198564T3 (fr)
HU (1)	HU228263B1 (fr)
ID (1)	ID16507A (fr)
IL (1)	IL126319A0 (fr)
MA (1)	MA24437A1 (fr)
MY (1)	MY117682A (fr)
NO (2)	NO311760B1 (fr)
NZ (1)	NZ332008A (fr)
OA (1)	OA11176A (fr)
PL (1)	PL188816B1 (fr)
PT (1)	PT889880E (fr)
RO (1)	RO118870B1 (fr)
SK (1)	SK282346B6 (fr)
TR (1)	TR199801954T2 (fr)
TW (1)	TW434239B (fr)
UA (1)	UA49880C2 (fr)
UY (1)	UY24504A1 (fr)
WO (1)	WO1997036874A1 (fr)
ZA (1)	ZA972686B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4475685B2 (ja) *	1997-06-27	2010-06-09	スミスクライン・ビーチャム・コーポレイション	エプロサルタン・一水和物
US6558699B2 (en) *	1997-11-17	2003-05-06	Smithkline Beecham Corporation	High drug load immediate and modified release oral dosage formulations and processes for their manufacture
HUP0004407A3 (en) *	1997-11-17	2002-03-28	Smithkline Beecham Corp	Immediate and modified release oral dosage formulations containing eprosartan and processes for their manufacture
WO1999044590A1 (fr)	1998-03-04	1999-09-10	Takeda Chemical Industries, Ltd.	Preparation a liberation prolongee d'un antagoniste de l'aii, sa production, et son utilisation
ZA991922B (en)	1998-03-11	1999-09-13	Smithkline Beecham Corp	Novel compositions of eprosartan.
TR200100172T2 (tr) *	1998-07-20	2001-05-21	Smithkline Beecham Corporation	Oral katı doz formunda eprosartan içeren biyolojik bakımdan kuvvetlendirilmiş formülasyonlar
GB9820405D0 (en) *	1998-09-18	1998-11-11	Smithkline Beecham Plc	Process
AU1157500A (en) *	1998-11-06	2000-05-29	Boehringer Ingelheim International Gmbh	Medicaments based on combinations of lacidipine and telmisartan or of physiological derivatives thereof
WO2000027397A1 (fr) *	1998-11-06	2000-05-18	Glaxo Group Limited	Medicaments antihypertenseurs a base de lacidipine et de telmisartan
CA2371554C (fr) *	1999-04-28	2009-06-09	Shizue Nakagawa	Composition pharmaceutique comportant un antagoniste de l'angiotensine ii pour la prevention, le traitement ou le blocage du developpement de la retinopathie simple et de la retinopathie preproliferative
GB9920917D0 (en)	1999-09-03	1999-11-10	Sb Pharmco Inc	Novel process
GB9920919D0 (en)	1999-09-03	1999-11-10	Sb Pharmco Inc	Novel compound
US20040023840A1 (en) *	2000-04-12	2004-02-05	Marc De Gasparo	Combination of organic compounds
BR0214383A (pt) *	2001-11-23	2004-11-03	Solvay Pharm Gmbh	Tratamento de hipertonia durante a fase aguda do ataque de apoplexia
KR100517638B1 (ko)	2002-04-08	2005-09-28	주식회사 엘지생명과학	게미플록사신 산염의 새로운 제조방법
EG24716A (en)	2002-05-17	2010-06-07	Novartis Ag	Combination of organic compounds
AU2003240670A1 (en) *	2002-05-17	2003-12-02	Novartis Ag	Combination of angiotensin ii receptor blocker and beta-blocker for secondary prevention of myocardial infarction
DE10230272A1 (de) *	2002-07-05	2004-01-22	Solvay Pharmaceuticals Gmbh	AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
JP3874419B2 (ja)	2003-01-31	2007-01-31	三共株式会社	動脈硬化及び高血圧症の予防及び治療のための医薬
WO2009013760A2 (fr)	2007-07-25	2009-01-29	Hetero Drugs Limited	Particules cristallines de mésylate d'éprosartan et procédé de préparation d'éprosartan pur
WO2009084028A2 (fr) *	2007-12-03	2009-07-09	Neuland Laboratories Ltd	Procédé amélioré de fabrication de méthanesulfonate de l'acide (e)-3-[2-butyl-1-{(4-carboxyphényl)méthyl}-1h-imidazol-5-yl]-(thiophén-2-ylméthyl)prop-2-énoïque
CN101333216A (zh)	2008-08-03	2008-12-31	浙江华海药业股份有限公司	一种新的依普罗沙坦甲磺酸盐成盐工艺
CN113354553B (zh) *	2021-06-03	2023-09-15	北京宝诺康医药科技有限公司	一种甲氧氯普胺单盐酸盐一水合物的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5185351A (en) *	1989-06-14	1993-02-09	Smithkline Beecham Corporation	Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
US5312828A (en) *	1989-06-14	1994-05-17	Finkelstein Joseph A	Substituted imidazoles having angiotensin II receptor blocking activity
JP3214856B2 (ja) *	1990-12-14	2001-10-02	スミスクライン・ビーチャム・コーポレイション	イミダゾリル−アルケン酸

1997
- 1997-03-26 UA UA98095006A patent/UA49880C2/uk unknown
- 1997-03-26 AU AU25470/97A patent/AU726694B2/en not_active Expired
- 1997-03-26 CZ CZ19983101A patent/CZ293345B6/cs not_active IP Right Cessation
- 1997-03-26 DE DE69721749T patent/DE69721749T2/de not_active Expired - Lifetime
- 1997-03-26 BR BR9708336A patent/BR9708336A/pt not_active IP Right Cessation
- 1997-03-26 AR ARP970101257A patent/AR006439A1/es active IP Right Grant
- 1997-03-26 EA EA199800873A patent/EA001958B1/ru not_active IP Right Cessation
- 1997-03-26 JP JP53538497A patent/JP4316013B2/ja not_active Expired - Lifetime
- 1997-03-26 MA MA24539A patent/MA24437A1/fr unknown
- 1997-03-26 UY UY24504A patent/UY24504A1/es not_active IP Right Cessation
- 1997-03-26 PT PT97917004T patent/PT889880E/pt unknown
- 1997-03-26 WO PCT/US1997/004877 patent/WO1997036874A1/fr not_active Ceased
- 1997-03-26 AT AT97917004T patent/ATE239723T1/de active
- 1997-03-26 TR TR1998/01954T patent/TR199801954T2/xx unknown
- 1997-03-26 NZ NZ332008A patent/NZ332008A/xx not_active IP Right Cessation
- 1997-03-26 EP EP97917004A patent/EP0889880B1/fr not_active Expired - Lifetime
- 1997-03-26 ES ES97917004T patent/ES2198564T3/es not_active Expired - Lifetime
- 1997-03-26 DK DK97917004T patent/DK0889880T3/da active
- 1997-03-26 RO RO98-01406A patent/RO118870B1/ro unknown
- 1997-03-26 HU HU9902769A patent/HU228263B1/hu unknown
- 1997-03-26 CN CN97193471A patent/CN1214682A/zh active Pending
- 1997-03-26 SK SK1322-98A patent/SK282346B6/sk not_active IP Right Cessation
- 1997-03-26 CA CA002250395A patent/CA2250395C/fr not_active Expired - Lifetime
- 1997-03-26 PL PL97329046A patent/PL188816B1/pl unknown
- 1997-03-26 IL IL12631997A patent/IL126319A0/xx active IP Right Grant
- 1997-03-27 MY MYPI97001335A patent/MY117682A/en unknown
- 1997-03-27 ZA ZA9702686A patent/ZA972686B/xx unknown
- 1997-03-27 AP APAP/P/1997/000956A patent/AP901A/en active
- 1997-03-27 EG EG24497A patent/EG23889A/xx active
- 1997-03-29 DZ DZ970046A patent/DZ2199A1/fr active
- 1997-03-31 ID IDP971059A patent/ID16507A/id unknown
- 1997-06-17 TW TW086108370A patent/TW434239B/zh not_active IP Right Cessation
1998
- 1998-09-28 NO NO19984503A patent/NO311760B1/no not_active IP Right Cessation
- 1998-09-29 OA OA9800184A patent/OA11176A/en unknown
- 1998-10-07 BG BG102822A patent/BG64095B1/bg unknown
2001
- 2001-06-09 CN CN01121133A patent/CN1332167A/zh active Pending
2002
- 2002-07-19 NO NO2002005C patent/NO2002005I1/no unknown

Also Published As

Publication number	Publication date
MY117682A (en)	2004-07-31
NO311760B1 (no)	2002-01-21
AR006439A1 (es)	1999-08-25
EA199800873A1 (ru)	1999-02-25
RO118870B1 (ro)	2003-12-30
BR9708336A (pt)	1999-08-03
AP901A (en)	2000-11-23
EG23889A (en)	2007-12-12
HUP9902769A3 (en)	2000-04-28
ATE239723T1 (de)	2003-05-15
CZ310198A3 (cs)	1999-03-17
NO984503L (no)	1998-09-28
CA2250395C (fr)	2005-09-06
PL188816B1 (pl)	2005-04-29
DZ2199A1 (fr)	2002-12-03
ZA972686B (en)	1997-09-29
AU726694B2 (en)	2000-11-16
WO1997036874A1 (fr)	1997-10-09
BG64095B1 (bg)	2003-12-31
CN1214682A (zh)	1999-04-21
DK0889880T3 (da)	2003-09-01
UY24504A1 (es)	1997-09-19
TR199801954T2 (xx)	1998-12-21
AP9700956A0 (en)	1997-04-30
OA11176A (en)	2003-05-13
BG102822A (en)	1999-11-30
AU2547097A (en)	1997-10-22
EP0889880A1 (fr)	1999-01-13
CZ293345B6 (cs)	2004-04-14
IL126319A0 (en)	1999-05-09
HUP9902769A2 (hu)	2000-03-28
PL329046A1 (en)	1999-03-01
NO984503D0 (no)	1998-09-28
CN1332167A (zh)	2002-01-23
EP0889880B1 (fr)	2003-05-07
DE69721749T2 (de)	2004-03-25
JP2000508632A (ja)	2000-07-11
PT889880E (pt)	2003-09-30
SK282346B6 (sk)	2002-01-07
UA49880C2 (uk)	2002-10-15
CA2250395A1 (fr)	1997-10-09
TW434239B (en)	2001-05-16
JP4316013B2 (ja)	2009-08-19
EP0889880A4 (fr)	1999-06-23
NZ332008A (en)	1999-05-28
HU228263B1 (en)	2013-02-28
EA001958B1 (ru)	2001-10-22
NO2002005I1 (no)	2002-09-02
HK1016594A1 (en)	1999-11-05
SK132298A3 (en)	1999-03-12
ES2198564T3 (es)	2004-02-01
ID16507A (id)	1997-10-02
DE69721749D1 (de)	2003-06-12

Publication	Publication Date	Title
ITMI950529A0 (it)	1995-03-17	Composizioni farmaceutiche e procedimento per la loro preparazione
NO961006L (no)	1996-09-16	Fosfonomononukleinsyrer, fremgangsmåter for fremstilling derav og anvendelse av forbindelsene
FR2722984B1 (fr)	1996-10-18	Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
MA23395A1 (fr)	1995-07-01	Procede de preparation de nouvelles formulations
IT1241679B (it)	1994-01-31	Perfluoropolieteri e processi per la loro preparazione
DZ2199A1 (fr)	2002-12-03	Dihydrate d'éprosartan et son procédé de préparation et sa formulation.
EP1183030A4 (fr)	2007-11-21	Procede de fabrication et d'application de n-desmethylzopiclone
FI971268A7 (fi)	1997-03-26	Menetelmä 1,3-alkaanidiolien ja 3-hydroksialdehydien valmistamiseksi
HUP9603527A2 (en)	1997-09-29	3-amino-2-mercaptobenzoic acid derivatives and processes for their and the intermediers preparation and the intermediers
ITMI951538A0 (it)	1995-07-14	Procedimento ed impianto per la disidratazione di foraggio particolarmente per la disidratazione dell'erba medica
TR199701051A3 (tr)	1999-03-22	2' -Fluoro-5-metil- -l-arabino-furanosilüridin hazirlanma prosesi
IT1237528B (it)	1993-06-08	Composti fotocromatici e termocromatici spiro-ossazepin-ossazine e procedimento per la loro preparazione
FR2732343B1 (fr)	1997-06-13	Composition de maltitol et son procede de preparation
EP0990632A4 (fr)	2004-04-14	Derives d'adamantanemethanol et procede de preparation de ces derniers
FR2764883B1 (fr)	1999-07-16	Procede de fabrication d'hydrofluoroalcanes
MA23663A1 (fr)	1996-04-01	Procede de preparation de formulations pharmaceutiques
EP0844017A4 (fr)	1999-09-01	Procede de preparation d'un emulsifiant et composition emulsionnee
FR2744648B1 (fr)	1998-03-20	Procede de preparation d'agents tensioactifs
FR2746261B1 (fr)	1998-05-07	Composition insecticide et procede de preparation
ITMI951417A0 (it)	1995-07-03	Composizioni farmaceutiche e procedimento per la loro preparazione
EP0823904A4 (fr)	1998-09-09	Procede de preparation de spiroindolines
FI971267L (fi)	1997-03-26	Menetelmä 1,3-alkaanidiolien ja 3-hydroksialdehydien valmistamiseksi
EP0761687A4 (fr)	2000-04-19	Procede de preparation d'un anticorps
EP0932601A4 (fr)	2000-02-02	Procede de preparation de composes pharmaceutiques
IT9020300A0 (it)	1990-05-14	3'-deamino-4'-deossi-4'-amino-8-fluoroantra- cicline e processi per la loro preparazione